Safety and Efficacy Study of Mitoxantrone Hydrochloride Liposome Injection Plus Cyclophosphamide,Vincristine and Prednison (CNOP)in Diffuse Large B Cell Lymphoma

Trial Profile

Safety and Efficacy Study of Mitoxantrone Hydrochloride Liposome Injection Plus Cyclophosphamide,Vincristine and Prednison (CNOP)in Diffuse Large B Cell Lymphoma

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 May 2017

At a glance

  • Drugs Mitoxantrone liposomal (Primary) ; Cyclophosphamide; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors CSPC ZhongQi Pharmaceutical Technology
  • Most Recent Events

    • 22 May 2017 Status changed from recruiting to withdrawn prior to enrolment.
    • 06 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top